Darzalex

J&J warns generics will bite its pharma unit in the second half
J&J warns generics will bite its pharma unit in the second half
Pharmaforum
JNJ
generics
biosimilars
Darzalex
Zytiga
Flag link:
FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex
FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex
Fierce Biotech
Sanofi
FDA
Darzalex
relapsed or refractory multiple myeloma
isatuximab
Flag link:
FDA quickly approves J&J’s Darzalex in multiple myeloma
FDA quickly approves J&J’s Darzalex in multiple myeloma
Pharmaforum
JNJ
Janssen
FDA
Darzalex
Multiple Myeloma
Flag link:
J&J bags $150M option on Genmab's Darzalex successor
J&J bags $150M option on Genmab's Darzalex successor
Fierce Biotech
Genmab
JNJ
Darzalex
Multiple Myeloma
drug development
Flag link:
ASCO: J&J eyes Darzalex convenience, safety boost with subcutaneous win
ASCO: J&J eyes Darzalex convenience, safety boost with subcutaneous win
Fierce Pharma
JNJ
Darzalex
ASCO 2019
Flag link:
J&J Seeks Approval for Darzalex in Expanded Patient Group
J&J Seeks Approval for Darzalex in Expanded Patient Group
Yahoo/Zacks.com
JNJ
Darzalex
Multiple Myeloma
FDA
Flag link:
Genmab's blockbuster Darzalex surpasses $2B in sales
Genmab's blockbuster Darzalex surpasses $2B in sales
BioCentury
Genmab
Multiple Myeloma
Darzalex
Flag link:
ASH: J&J's fast-growing Darzalex lines up for second front-line myeloma OK
ASH: J&J's fast-growing Darzalex lines up for second front-line myeloma OK
Fierce Pharma
JNJ
Darzalex
Multiple Myeloma
ASH 2018
Flag link:
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
BioSpace
JNJ
Janssen
Genmab
Darzalex
clinical trials
Multiple Myeloma
Flag link:
Johnson & Johnson Seeks EU and US Label Expansion for Darzalex
Johnson & Johnson Seeks EU and US Label Expansion for Darzalex
Market Realist
JNJ
Janssen
Darzalex
daratumumab
Europe
Multiple Myeloma
Flag link:
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Xconomy
clinical trials
Roche
Genentech
Genmab
JNJ
cancer
Tecentriq
Darzalex
Flag link:
Danish biotech Genmab hit by ending of trial using key cancer drug
Danish biotech Genmab hit by ending of trial using key cancer drug
Reuters
Genmab
JNJ
Janssen
Darzalex
Flag link:
Janssen obtains FDA approval for Darzalex (multiple myeloma)
Janssen obtains FDA approval for Darzalex (multiple myeloma)
GoinPharma
Janssen
JNJ
Darzalex
Takeda
Velcade
Multiple Myeloma
FDA
Flag link:
3 Drugs That Are Moving the Needle at Johnson & Johnson
3 Drugs That Are Moving the Needle at Johnson & Johnson
Motley Fool
JNJ
Darzalex
Zytiga
Stelara
earnings
Flag link:
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Motley Fool
JNJ
Stelara
Zytiga
Darzalex
oncology
immunology
Flag link:
ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half
ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half
Fierce Pharma
ASH17
JNJ
Darzalex
Multiple Myeloma
Janssen
Flag link:
Genmab and J&J 'love' partnership as some ponder takeover
Genmab and J&J 'love' partnership as some ponder takeover
Yahoo/Reuters
Genmab
JNJ
M&A
Darzalex
Flag link:
J&J multiple myeloma drug succeeds in first-line combination study
J&J multiple myeloma drug succeeds in first-line combination study
Yahoo/Reuters
JNJ
Multiple Myeloma
clinical trials
Darzalex
Flag link:
5 Key Drugs Critical to Johnson & Johnson's Future
5 Key Drugs Critical to Johnson & Johnson's Future
Motley Fool
JNJ
Stelara
Xarelto
Imbruvia
Zytiga
Darzalex
Flag link:
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Motley Fool
JNJ
Remicade
Stelara
drug pricing
Imbruvica
Xarelto
Darzalex
devices
consumer health
Flag link:

Pages